Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 18

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 18
---
 among the Company and DiamiR dated July14, 2025, pursuant to which the Company shall acquire 100% of DiamiR outstanding shares of common stock in exchange for shares consideration after which, DiamiR will become the Company’s wholly -ownedsubsidiary, and the existing DiamiR stockholders and existing Company shareholders will own approximately 70% and 30%, respectively, of the outstanding shares of the post -closingCompany. •“EEA” refers to the European Economic Area. •“EMA” refers to the European Medicines Agency. •“EMEA” refers to Europe, the Middle East and Africa. •“EPO” refers to the European Patent Organization or the European Patent Office operated by it. •“European Patent” refers to patents issuable by the EPO. •“EU” refers to the European Union. •“Exchange Act” refers to the U.S. Securities Exchange Act of 1934, as amended. •“FDA” refers to U.S. Food and Drug Administration. •“FDCA” refers to the U.S. Federal Food, Drug and Cosmetic Act. •“Fiscal year” refers to the period from January 1 of each calendar year to December 31 of the same calendar year. •“HKD” refers to Hong Kong Dollars. •“Hong Kong” or “H.K.” refers to Hong Kong Special Administrative Region of the People’s Republic of China. •“IND” refers to Investigational New Drugs. •“IP” refers to intellectual property. •“IPO” or “Offering” means the initial public offering by the Company of 76,142 Class A ordinary shares consummated on December17, 2018. •“IVD” refers to an in vitrodiagnostic. •“Jurchen” refers to Jurchen Investment Corporation, a company wholly -ownedby our Chief Executive Officer and director, Ian Huen, and a holding company of Aptorum Group. •“Laboratory” refers to DiamiR’s laboratory in New Haven, CT, unless otherwise noted. •“LDT” refers to lab -developedtest. An LDT is an in vitrodiagnostic (IVD) test that is designed, manufactured, and performed within a single laboratory. The development of the lab -developedtest includes custom assay design and validation of the test system, including accuracy and replicability of the test. •“Lead Projects” refers to ALS -4and SACT -1